Abstract. p60 is a subunit of katanin involved in microtubule-severing. Previous studies of p60 were primarily focused on microtubule regulation and cell cycle regulation. More recent research has demonstrated that katanin p60 possesses a function in prostate cancer bone metastasis; however, its role in breast cancer bone metastasis remains unclear. In the present study, immunohistochemistry was used to analyze the expression of katanin p60 in primary and bone metastatic breast cancer. The role of up-and downregulated katanin p60 was investigated using cell proliferation, and migration experiments. Overall, katanin p60 was highly expressed in breast cancer bone metastatic tissue compared with primary tumor tissue. In breast cancer cells, overexpression of katanin p60 inhibited cell proliferation, but promoted cell migration, whereas silencing katanin p60 expression promoted cell proliferation but inhibited cell migration. Overall, the present study indicated that katanin p60 serves a role in cell proliferation and migration, and thus may be a novel therapeutic target for prevention of breast cancer metastasis.
Introduction
Breast cancer is among the most commonly diagnosed types of malignant tumor in women worldwide (1) . Bone is the most common site of distant metastasis in patients with breast cancer and >70% of all patients with breast cancer eventually develop bone metastases, which presents clinical challenges (2) . There is an increased risk of mortality for patients with breast cancer once bone metastasis has occurred (3) . Therefore, elucidation of the mechanism of breast cancer bone metastasis is required for the identification of novel therapeutic targets for the prevention or control of bone metastasis.
Metastasis is associated with the migratory ability of tumor cells. Pseudopodia form through the rearrangement of the cell cytoskeleton and serve key roles in cell migration (4) . Microtubules are essential for pseudopodia extension and regulation of cell movement, katanin is an ATPase that causes microtubule degradation (5) (6) (7) . Katanin consists of p60 and p80 subunits (8) ; p80 targets the p60 subunit to the centrosome, and promotes the microtubule-severing activity of p60 (9) . Research has demonstrated that leucine zipper tumor suppressor 2 (LAPSER1) and katanin p80 co-localize in the centrosome, and are involved in mitosis and cell movement (10) . However, the activity of the p60 subunit remains poorly characterized and requires further research.
p60 is a 60-kDa enzymatic subunit containing an ATPases associated with diverse cellular activities (AAA) domain, which is responsible for microtubule-severing activity (11) and directly regulates microtubule-severing by phosphorylating katanin p60 at the Ser131 site (12) . E3 ubiquitin ligases participate in the degradation of katanin p60 (13, 14) . In the context of disease, research into p60 function has primarily focused on the role of p60 in neurogenesis (15) (16) (17) . To the best of our knowledge, the expression of katanin p60 in tumor metastasis has only been reported in prostate cancer (18) , and its role in breast cancer is unknown. In the present study, the distribution and expression of katanin p60 in clinical breast cancer specimens was investigated, and it was determined whether katanin p60 was involved in breast cancer cell proliferation or promotion of breast cancer bone metastasis.
Materials and methods
Cell culture. The triple negative breast cancer cell line, MDA-MB-231 and metastatic invasive ductal carcinoma cell line, MCF-7 were purchased from the Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China). Cells were cultured in DMEM (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% fetal calf serum (FCS; Gibco; Thermo Fisher Scientific, Inc.), 100 U/ml penicillin and 100 U/ml streptomycin (Beyotime Institute of Biotechnology, Shanghai, China) at 37˚C in 5% CO 2 .
Tissue samples and immunohistochemistry. The primary breast cancer specimens and breast cancer bone metastases specimens were divided into primary, and metastasis groups, when the cell confluence reached 50-70%. Two cell lines were transfected under the same condition. A total of 1800 µl Opti-MEM (Gibco; Thermo Fisher Scientific, Inc.) was added to each well, followed by a mixture of 2 µg plasmid DNA, 6 µl X-tremeGENE transfection reagent (Roche, Basel, Switzerland) and 200 µl Opti-MEM, the control group was cultured only with Opti-MEM. Following an incubation of 5 h at 37˚C, cells were collected at different time points for subsequent studies. The transfection efficiency was detected by western blotting and reverse transcription-quantitative polymerase chain reaction (RT-qPCR).
shRNA. The shRNAs were constructed and identified by Chongqing Weisiteng Biomedical Science and Technology Co., Ltd., and the sequences were as follows: shRNA-KATNA1, forward, 5'-GGU UCA GAU GG AU GGU GUU TT-3' and reverse, 5'-AAC ACC AUC CA UC UGA ACC TT-3'); shRNA-negative control (NC), forward, 5'-UUC UCC GAA CGU GUC ACG UTT-3' and reverse, 5'-ACG UGA CAC GUU CGG AGA ATT-3'). A total of 9 µl Lipofectamine ® 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) diluted in Opti-MEM and 3 µg shRNA-NC or shRNA-KATNA1 (0.5 µg/µl) diluted in Opti-MEM were mixed for 20 min, then the mixture was added into MDA-MB-231 or MCF-7 cells (6-well plates) for 6 h at 37˚C, the transfection efficiency be detected by western blotting analysis and RT-qPCR.
RNA isolation and RT-qPCR. Cells were collected after transfected with plasmids or shRNAs for 48 h. At room temperature, total RNA was extracted with TRIzol (Thermo Fisher Scientific, Inc.) for 5 min, reacted with chloroform for 2-3 min, isopropanol for 10 min and 75% ethanol for 1 min sequentially, then RNA was dissolved in 0.1% diethyl pyrocarbonate (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany). The concentration and purity of RNA were measured using a spectrophotometer (GE Healthcare, Chicago, IL, USA). Reverse transcription was performed using PrimeScript™ 1st strand cDNA Synthesis Kit (cat no. 6610A; Takara Biomedical Technology, Beijing, China), for 10 min at 25˚C, 50 min at 42˚C and 5 min at 85˚C. qPCR analysis was performed using SYBR ® Premix DimerEraser™ (Perfect Real Time; cat no. RR091A; Takara Biomedical Technology). The primer sequences were as follows: Katanin p60, forward, 5'-TAA ACT GGA CAG CAC TCC CTT G-3' and reverse, 5'-CCT GGT GAG GGT CTT CGT TC-3'; actin, forward, 5'TGA CGT GGA CAT CCG CAA AG-3' and reverse, 5'-CTG GAA GGT GGA CAG CGA GG-3'. The thermocycling parameters were as follows: 94˚C for 4 min; 35 cycles of 94˚C for 20 sec, 60˚C for 30 sec and 72˚C for 30 sec. The relative expression of katanin p60 was obtained according to the 2 -ΔΔCq method (19) .
Western blot analysis. After transfected with shRNAs or plasmids for 48 h, cells were lysed using radioimmunoprecipitation assay buffer containing 1% Triton X-100, 1% sodium deoxycholate and 0.1% SDS (0.1 ml/1x10 6 cells; Beyotime Institute of Biotechnology). Total protein was extracted and its concentration was measured using a BCA protein assay kit (Beyotime Institute of Biotechnology). Extracted proteins (50 µg) were separated by SDS-PAGE (5% stacking gels, 12% resolving gels) and transferred into a nitrocellulose membrane. Subsequent to blocking with 5% skim milk (GE Healthcare, Chicago, IL, USA) for 2 h at room temperature, the membranes were washed and incubated with anti-katanin p60 antibody (dilution, 1:500; Abcam, Cambridge, UK) and anti-GADPH antibody (dilution, 1:1,000; Abcam) overnight at 4˚C. Then the membranes were washed with 1X TBST buffer (pH 7.6; 2.42 g/l Tris, 8 g/l NaCl, 0.5 ml Tween-20) and incubated with the peroxidase-conjugated anti-rabbit secondary antibody (dilution, 1:1,000; cat no. A0545; Sigma-Aldrich; Merck KGaA) for 90 min at room temperature, an ECL chemiluminescence kit (Pierce; Thermo Fisher Scientific, Inc.) was used to visualize the proteins. Densitometry was performed using ImageJ software (version 1.46; National Institutes of Health, Bethesda, MD, USA).
Cell proliferation assay. Un-transfected group, negative control and shRNA-KATNA1 or pcDNA3.1/KATNA1-transfected cells were seeded into 96-well plates at 1x10 4 cells/well for 24, 48, 72 and 96 h. Cells were cultured with 10 µl MTT (5 mg/ml; Sigma-Aldrich; Merck KGaA) for 4-6 h, then 150 µl dimethyl sulfoxide was added (Amresco, LLC, Solon, OH, USA) and incubated for 10 min. Subsequently, the absorbance was measured using a multimode reader at 490 nm. Each experiment was repeated three times for construction of the growth curve.
Cell migration assay. Un-transfected group, negative control and shRNA-KATNA1 or pcDNA3.1/KATNA1-transfected cells were cultured for 24 h. Then, 2.5x10 4 cells were added to the upper chamber of Transwell filters, a total of 200 µl DMEM supplemented with 5% BSA (Gibco; Thermo Fisher Scientific, Inc.) was added to each lower chamber, and incubated for 24 h at 37˚C. The cells were fixed with 70% formaldehyde for 30-60 min and stained with 0.1% crystal violet for 30 min (Sigma-Aldrich; Merck KGaA) at room temperature, and the number of migrated cells was counted using ImageJ software (version 1.46; National Institutes of Health).
Statistical analysis. All data were analyzed by SPSS 17.0 software (SPSS, Inc., Chicago, IL, USA) and expressed as the mean ± standard error. Student's t-test was used to determine the statistical significance. P<0.05 was considered to indicate a statistically significant difference.
Results

Expression of katanin p60 in breast cancer and bone metastasis.
It has been demonstrated that the expression of katanin p60 contributes to the progression of prostate cancer, indicated that katanin p60 may also serve an important role in breast cancer (18) . To test this hypothesis, immunohistochemical staining of tissues with an anti-katanin p60 antibody (Table I) was performed. Low expression of katanin p60 was exhibited in healthy breast tissue, and katanin p60 expression was primarily identified in the cytoplasm (Fig. 1A) . The expression of katanin p60 was significantly increased in primary breast cancer tissue compared with healthy control tissue (178.96±13.81%; P=0.001; Fig. 1B ). In bone metastatic breast cancer, the expression of katanin p60 was further increased when compared with healthy breast tissue (231.48±16.00%; P=0.001), and with primary breast cancer (P=0.023; Fig. 1B ).
Together, these data indicate that katanin p60 may function in the regulation of breast cancer cell proliferation and migration.
Up-or downregulation of katanin p60.
To determine the function of katanin p60 in breast cancer cells, plasmids and shRNAs were utilized to up-or downregulate its expression. RT-qPCR and western blotting were used to detect the expression of katanin p60 at the mRNA, and protein levels.
In MDA-MB-231 cells and MCF-7 cells, the expression of katanin p60 was significantly increased following transfection with pcDNA3.1/KATNA1 (Fig. 2) . In addition, the protein and mRNA levels of katanin p60 were significantly decreased following transfection with shRNA-KATNA1 (Fig. 2) .
Function of katanin p60 on cell proliferation. To further investigate whether katanin p60 was involved in the regulation of cell proliferation, cells were collected at 24, 48, 72 and 96 h after transfection with plasmids or shRNAs (Fig. 3) . The present study demonstrated no significant difference in cell proliferation between MDA-MB-231 and MCF-7 cells. Upregulation of katanin p60 expression with pcDNA3.1/KATNA1 reduced cell proliferation, the percentage of proliferating cells at 24 h was 40.72±2.54% for MDA-MB-231 cells and 56.82±1.34% for MCF-7 cells (Fig. 3A and B) . No significant differences in cell proliferation were identified compared with the shRNA-NC group at 24 or 48 h following transfection with shRNA-KATNA1; however, the percentage of proliferating cells at 72 h was significantly increased, at 126.64±0.88% in MDA-MB-231 cells and 122.03±0.56% in MCF-7 cells (Fig. 3C and D) . This indicates that katanin p60 may serve a role in breast cancer cell proliferation.
Katanin p60 is necessary for cell migration. To investigate whether katanin p60 was involved in cell migration, plasmids or shRNAs were transfected into cells to achieve up-and downregulation of p60, respectively, and the resultant effects on cell migration were analyzed. It was demonstrated that upregulation of katanin p60 expression accelerated cell migration in MDA-MB-231 and MCF-7 cells compared with pcDNA3.1 cells, with fold changes of 162.95±6.20% and 161.84±11.23% (Fig. 4A) . Downregulated expression of katanin p60 reduced cell mobility in MDA-MB-231 cells (43.78±3.28%) and MCF-7 cells (36.18±4.23%) compared with shRNA-NC cells (Fig. 4B) . No significant difference was identified in the metastatic rate between the two cell lines. These results indicated that katanin p60 may promote tumor cell spread to other sites, and are supportive of the aforementioned results achieved in breast cancer tissue specimens and bone metastasis tissue specimens.
Discussion
Katanin p60 contains an N-terminal domain that is connected with microtubules, which are required for cell motility and spindle formation (11) . Previous studies have reported that katanin p60 oligomerization increases the affinity of katanin for microtubules, thus increasing microtubule degradation (20, 21) . In the present study, it was demonstrated that katanin p60, a member of the AAA ATPase family, was expressed differently between healthy breast tissue specimens, primary and bone metastatic breast cancer specimens. The expression of katanin p60 in bone metastatic breast cancer was significantly higher, which was positively associated with tumor metastasis, indicating that katanin p60 may serve a role in breast cancer cell proliferation and metastasis.
The present study demonstrates that the expression levels of katanin p60 mRNA and protein increased significantly subsequent to transfection with pcDNA3.1/KATNA1. Simultaneously, the number of breast cancer cells decreased. Downregulation of katanin p60 expression using shRNA resulted in an increased cell number. These results indicate that katanin p60 expression and cell proliferation are positively associated. Previous research has reported an association between katanin p60 expression and cell proliferation (18) . Spindle length is controlled by katanin in mitosis and meiosis, essential for chromosome segregation and cytokinesis (22) . Katanin p60 has also been demonstrated to facilitate microtubule instability (23) . Microtubule binding by the katanin p60 subunit is important for katanin in targeting the spindle poles (24) . These studies suggest that katanin p60 may affect cell division by regulating spindle length.
Cell migration is an essential process in tumor metastasis. Previous studies have indicated that pseudopodial protrusion is associated with tumor cell migration and invasion (25, 26) . Drosophila katanin p60 is reported to regulate the interactions of the cortical-microtubule plus-end, which is involved in cell migration (27) . The appropriate distribution and content of katanin p60 has been demonstrated as critical for neuronal migration (28) . The present study confirmed that overexpression of katanin p60 significantly promoted cell migration, and reduced expression inhibited cell migration in MDA-MB-231 and MCF-7 cell lines. Therefore, it is hypothesized that katanin p60 may affect breast cancer cell migration by regulating the formation of cellular pseudopodia.
Overall, the present study supports the concept that katanin p60 functions in cell proliferation and migration. A previous study reported that purine-type compounds interact with katanin p60, which induce cell death of NSCLC cells (29) . Together, these results suggest that katanin p60 is required for breast cancer cell proliferation and bone metastases, and, therefore, has exciting potential as a therapeutic target. Future research by this group will focus on the association between katanin p60, spindle and cellular pseudopodia in breast cancer cells, in order to further elucidate the regulatory mechanisms of katanin p60. 
